These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 20580619

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
    Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.
    Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
    Davis KL, Candrilli SD, Edin HM.
    Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [The clinical and economic impact of generic drugs in the treatment of epilepsy].
    Argumosa A, Herranz JL.
    Rev Neurol; 2008 Mar; 41(1):45-9. PubMed ID: 15999330
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
    LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O.
    Neurology; 2008 May 27; 70(22 Pt 2):2179-86. PubMed ID: 18505997
    [Abstract] [Full Text] [Related]

  • 10. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
    Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Crémieux PY.
    Dis Manag; 2007 Aug 27; 10(4):216-25. PubMed ID: 17718660
    [Abstract] [Full Text] [Related]

  • 11. The risks and costs of multiple-generic substitution of topiramate.
    Duh MS, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J.
    Neurology; 2009 Jun 16; 72(24):2122-9. PubMed ID: 19528520
    [Abstract] [Full Text] [Related]

  • 12. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy.
    Ettinger AB, Manjunath R, Candrilli SD, Davis KL.
    Epilepsy Behav; 2009 Feb 16; 14(2):324-9. PubMed ID: 19028602
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC, Le L, Ramsey SD, Solow BK, Zakharyan A, Stockl KM, Harada AS, Curtis B.
    Epilepsia; 2011 Jul 16; 52(7):1365-71. PubMed ID: 21692778
    [Abstract] [Full Text] [Related]

  • 16. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M.
    Epilepsia; 2007 Oct 16; 48(10):1825-32. PubMed ID: 17850324
    [Abstract] [Full Text] [Related]

  • 17. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F, Duh MS, Gosselin A, Paradis PE.
    Epilepsia; 2007 Mar 16; 48(3):464-9. PubMed ID: 17346246
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
    Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS.
    Neurology; 2008 Aug 12; 71(7):525-30. PubMed ID: 18695164
    [Abstract] [Full Text] [Related]

  • 20. Effects of antiepileptic drug substitutions on epileptic events requiring acute care.
    Rascati KL, Richards KM, Johnsrud MT, Mann TA.
    Pharmacotherapy; 2009 Jul 12; 29(7):769-74. PubMed ID: 19558250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.